Background Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus
disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and …

Regardless of vaccination status, progression to severe coronavirus disease 2019 (COVID‐
19) is still a relevant cause of morbidity among immunocompromised patients. Despite the …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Importance Older patients living in nursing homes are at very high risk of mortality after
getting COVID-19. Objective To evaluate outcomes following oral antiviral treatment for …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Background: In addition to supportive therapy, antiviral therapy is an effective treatment for
coronavirus disease 2019 (COVID-19). Objective: To compare the efficacy and safety of …

Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic agents that target severe acute respiratory syndrome …

Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …

Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …